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Abstract
Background: Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a
CAG repeat expansion mutation in the coding region of a novel gene. The mechanism of HD is
unknown. Most data suggest that polyglutamine-mediated aggregation associated with expression
of mutant huntingtin protein (mhtt) contributes to the pathology. However, recent studies have
identified early cellular dysfunctions that preclude aggregate formation. Suppression of aggregation
is accepted as one of the markers of successful therapeutic approaches. Previously, we
demonstrated that tricyclic pyrone (TP) compounds efficiently inhibited formation of amyloid-β
(Aβ) aggregates in cell and mouse models representing Alzheimer's Disease (AD). In the present
study, we aimed to determine whether TP compounds could prevent aggregation and restore early
cellular defects in primary embryonic striatal neurons from animal model representing HD.
Results: TP compounds effectively inhibit aggregation caused by mhtt in neurons and glial cells.
Treatment with TP compounds also alleviated cholesterol accumulation and restored clathrin-
independent endocytosis in HD neurons.
Conclusion: We have found that TP compounds not only blocked mhtt-induced aggregation, but
also alleviated early cellular dysfunctions that preclude aggregate formation. Our data suggest TP
molecules may be used as lead compounds for prevention or treatment of multiple
neurodegenerative diseases including HD and AD.
Background
Huntington's Disease (HD) is one of several hereditary
progressive neurodegenerative disorders caused by expan-
sion of a CAG repeat in the respective disease genes. In
HD, unstable CAG expansion within the coding region of
the IT15 gene is translated into an abnormally long poly-
glutamine tract near the N-terminus of the protein called
huntingtin (htt) [1-3]. While mutation analysis and trans-
genic animal models for disease have unequivocally iden-
tified the expanded polyglutamine tract as key in toxicity
[4,5], the mechanism by which mutant htt (mhtt) pro-
gressively kills brain cells is poorly understood.
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Long polyglutamine tracts are known to form hydrogen
bonded, β-sheets ("polar zippers") that are prone to aggre-
gation [6,7]. Indeed, aggregates called inclusion bodies
have been identified in human disease tissue for all poly-
glutamine disorders [8,9]. Aggregates were found to affect
vital cellular functions and accelerate cell death [10]. Sup-
pression of aggregate formation has been shown to be
beneficial in cell models for HD and is accepted as one of
the markers of successful therapeutic approaches [11].
Consequently, aggregate formation has served as a pheno-
type in screening of small molecules and peptides for their
inhibitory properties that promote cell survival in mhtt-
expressing cells [12]. Screening of the NINDS Custom
Collection of FDA approved drugs for their ability to pre-
vent aggregation has produced a number of compounds
including gossypol, gambogic acid, juglone, celastrol, san-
guinarine and anthralin. Although each compound effec-
tively reversed aggregation of amino terminal fragment of
mutant huntingtin (1–171) with 58 polyglutamines in
vitro, none of these molecules was effective in promoting
survival of R6/2 mice, a model representing the most
severe HD phenotype [12]. Thus, blocking aggregate for-
mation, by itself, may not be a definitive predictor of the
efficiency of potential therapeutics. Additionally, mhtt
has multiple cellular interacting partners and confers
many adverse effects in cells [13]. Since no single physio-
logical process has yet been identified as the primary ther-
apeutic target, better functional screening phenotypes
would be necessary in order to evaluate the effectiveness
of particular compounds.
We have previously synthesized and examined the biolog-
ical activity of a number of tricyclic pyrone (TP) analogs
and found that TP compounds directly bind to and inhibit
formation of amyloid-β (Aβ) aggregates in cell model rep-
resenting Alzheimer's Disease (AD) [14-16]. Moreover, 2-
week treatment with CP2 (Figure 1A) dramatically
reduced formation of non-fibrillar and fibrillar Aβ oli-
gomers in vivo in mouse model representing familial AD
[16]. Thus, TPs represent a promising class of compounds
with anti-aggregate properties. However, whether TP com-
pounds could prevent aggregate formation in other neu-
Chemical structures of TP compounds utilized in the study and synthesis of compound TP4 Figure 1
Chemical structures of TP compounds utilized in the study and synthesis of compound TP4. TFA – trifluoracetic 
acid; THF – tetrahydrofuran; HMPA – hexamethylphophoramide.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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rodegenerative disorders has not been studied. It is also
unknown whether TP compounds could ameliorate ear-
lier cellular defects that preclude aggregate formation in
the cells.
In our early study, we have established a cellular model
that allowed assessment of the effect of mhtt-induced
aggregate formation on survival of primary neurons, cells
that are most vulnerable in HD [17]. In this model, trans-
fection of primary neurons from control mice with GFP-
tagged truncated mhtt fragment (with 82 polyglutamines)
caused rapid formation of aggregates that marked late
events in HD progression. Recently, we identified cellular
dysfunctions that arise early in disease progression prior
to aggregate formation. We demonstrated that expression
of full-length mhtt causes cholesterol accumulation and
inhibition of clathrin-independent caveolin-1 (cav-1)-
related endocytosis in embryonic striatal neurons from
HD72 mice [18,19]. These observations lead us to test
whether TP compounds could effectively prevent mhtt-
induced aggregation and restore early cellular defects
associated with HD. We also reported synthesis and eval-
uation of biological activity of a new TP compound, TP4
(Figure 1C), which was modified to possess higher func-
tionality and ability to penetrate blood-brain barrier. We
found that treatment with TP compounds not only pre-
vented aggregate formation caused by expression of trun-
cated form of mhtt in both primary neurons and glial
cells, but also reduced cholesterol accumulation and
restored endocytosis inhibited by expression of full-
length mhtt.
Results
Synthesis of a new tricyclic pyrone analogue, TP4
Previously, we found that tricyclic pyrone molecules, CP2
and TP3, inhibit formation of toxic Aβ oligomers and pre-
vent cell death in MC65 cells conditionally expressing a
partial  β APP fusion protein (amino-17 residues+car-
boxyl-99 residues; SβC), C99 [14-16,20-22]. Structurally,
CP2 and TP3 compounds consist of a tricyclic pyranopy-
rone skeleton and an adenine moiety attached on its N3'
or N9' to the C7 isopropyl group of the fused cyclohexane
ring (Figure 1A, B). The N3'-molecule, CP2, is ten times
more efficient in preventing cell death in MC65 cells than
the N9'-derivative TP3 [14]. However, the bioactivity of
TP compounds where the methyl group at C3 atom will
be substituted with other groups that could enhance their
solubility in water has not been examined. To investigate
the effect of C3-substituent, we synthesized a CP2 ana-
logue, TP4 (Figure 1C), possessing an acetoxyethyl group
at C3 and compared its biological activity with that of CP2
and TP3. We previously synthesized CP2 and TP3 com-
pounds via a sequence of reactions starting from com-
pound  1  (Figure 1C), derived from a one-pot
condensation reaction of 4-hydroxy-6-methyl-2-pyrone
and (S)-(-)-perillaldehyde [22]. Compound TP4 was sim-
ilarly synthesized from compound 1  (Figure 1C) by a
deprotonation with lithium diisopropylamide (LDA) fol-
lowed by formaldehyde and then acetic anhydride (Ac2O)
to give compound 2. It should be noted that the hydroxyl
intermediate derived from the reaction of compound 1
with formaldehyde is an unstable compound, which
undergoes reverse aldol reaction to produce compound 1
and formaldehyde under weakly acidic conditions.
Hence, protection of the hydroxyl function with an acetyl
moiety is needed. Selective hydroxylation of compound 2
with boraneTHF followed by oxidation with NaOH-
H2O2, mesylation of the resulting hydroxyl function with
methanesulfonyl chloride (MsCl), and displacement with
adenine in N, N-dimethylacetamide (DMA) afforded TP4.
CP2, TP3 and TP4 were purified using HPLC with ace-
tonitrile, water and trifluoroacetic acid (TFA) (1%) as sol-
vents. The pure solids obtained after lyophilization were
stable water-soluble TFA salts.
Treatment with TP compounds at low concentrations does 
not cause toxicity in embryonic neurons
Effective pharmacological compounds must be non-toxic
to cells. To evaluate the toxicity of TP compounds, pri-
mary embryonic (E17) striatal neurons from FVB control
mice were cultured and treated next day after plating with
0, 2, 5, 10, 20 and 40 μM of different TPs. Cells were kept
under these conditions for 13 days. Every other day, the
neuronal morphology and the extent of cell death were
evaluated by imaging of five randomly selected fields (Fig-
ure 2A). For all TP compounds tested, concentrations
below 5 μM did not cause significant cell death for up to
13 days in culture (Figure 2A, 2 μM). About 60% of neu-
rons remain healthy and preserve their morphology.
However, concentrations above 5 μM effectively killed
cells in less than 7 days (Figure 2A, 40 μM). At day 6 in
culture, for each TP compound, we determined the lethal
dose at which 50% of the cells died (LD50) (Figure 2B).
The results suggested concentrations between 2 and 5 μM
were least toxic for all TPs tested. Survival of HD neurons
in response to TP treatments did not differ from control
cells (data not shown). Thus, we used these conditions in
the following experiments.
Treatment with CP2 inhibits aggregation in primary 
embryonic neurons expressing mhtt
Previously, we have shown that treatment with CP2 and
TP3 effectively prevent Aβ aggregation in cell and animal
model for AD [14,16]. Therefore, we tested whether TP
compounds can also prevent aggregation caused by
expression of mhtt. It has been well documented, that
expression of a truncated form of mhtt with expanded
polyglutamine region leads to rapid formation of intracel-
lular aggregates [17]. Indeed, transfection of neuronal cul-
tures from control mice with GFP-HD82, a truncated formBMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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Treatment with TP compounds at low concentrations is not toxic for primary neuronal cultures Figure 2
Treatment with TP compounds at low concentrations is not toxic for primary neuronal cultures. A. Survival of 
primary striatal neurons from control mice treated with different concentrations of CP2. Days in culture (DIC) and CP2 con-
centrations are indicated. Images were acquired using LSM 510 confocal microscope with 63 × or 100 × oil DIC lenses (1.4 na). 
Scale bars, 20 um. B. Lethal dose at which 50% of the neurons died (LD50) for all three TP compounds was estimated at day 6 
after plating using LIVE/DEAD assay.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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of human htt (amino acid 1–221) with pathologic 82 pol-
yglutamine repeats, leads to rapid formation of visible
aggregates in both primary striatal neurons and glial cells
within 2–10 hours post transfection (Figure 3A, a, &3A, b
). Aggregates are visible as green puncta indicated with
arrows). However, treatment of striatal cultures with CP2
from the day of plating eliminated formation of inclu-
sions in neurons and reduced aggregate formation in glial
cells by 90% relative to untreated cells (Figures 3A, c &3A,
d, &3B). Aggregation was specific to expression of GFP-
mhtt with expanded polyglutamine tract since no aggre-
gates were formed in cells transfected with control plas-
mid expressing a short GFP-htt fragment with 19
polyglutamines (non-pathologic length, GFP-HD19)
(Figure 3A, e &3A, f). Thus, CP2 efficiently inhibited
aggregation caused by expression of truncated form of
mhtt in neurons and glial cells at the concentrations as
low as 2 μM.
Treatments with TP compounds do not affect the 
expression of mhtt
Control experiments were performed to examine the
effects of TP compounds on the expression of mhtt. We
plated neurons from HD mouse and treated cells with dif-
ferent doses of CP2 (2 and 5 μM), TP3 (2 μM), and TP4 (2
μM) for 6 days starting from the first day of plating.
Treated and untreated HD cells were collected, lysed, and
subjected to the Western Blot analysis using specific mon-
oclonal anti-huntingtin antibody 2166 (1:3000, Chemi-
con) as previously described [17,18]. Results are shown in
Figure 3C and data indicated that treatments with TP com-
pounds do not affect expression of mhtt in primary neu-
rons from HD mice (similarly, TP compounds do not
affect the expression of cav-1; data not shown).
Treatment with CP2 restores clathrin-independent 
endocytosis inhibited by expression of mhtt
Since aggregate formation is a late event in disease pro-
gression, we next investigated whether CP2 treatment
could alleviate early cellular dysfunctions associated with
HD. Recently, we have shown that expression of full-
length mhtt causes abnormal cholesterol accumulation
and inhibition of clathrin-independent caveolin-related
endocytosis in embryonic striatal neurons from HD72
mice early in disease progression prior to aggregate forma-
tion [18]. Thus, we first tested whether CP2 treatment
could restore defective endocytosis associated with mhtt
expression in striatal neurons from HD72 mice.
Internalization of essential extracellular components in
neurons occurs through multiple endocytic pathways
including clathrin-dependent and clathrin-independent
caveolin-related endocytosis [23]. In order to evaluate
whether CP2 treatment could restore defective endocyto-
sis in HD72 neurons, we monitored internalization of flu-
orescently labelled cargoes specific for each pathway.
Alexa Fluor 594-labeled transferrin, Tfn, was used as a
marker for clathrin-mediated endocytosis [24], and BOD-
IPY-lactosylceramide, LacCer, as a marker for clathrin-
independent caveolin-related endocytosis [25]. Consist-
ent with previous observations, expression of mhtt had no
effect on Tfn internalization in HD72 neurons comparing
to control cells (Figure 4A, C). Treatment with either 2 or
5 μM of CP2 also did not affect Tfn internalization or
intracellular localization in HD72 neurons comparing to
control or untreated HD72 cells (Figure 4A, C). These data
suggest that neither CP2 treatment nor mhtt expression
affected clathrin-mediated endocytosis in striatal neurons.
In contrast, the uptake of LacCer was inhibited by 70% in
HD neurons relative to control cells (Figure 4B, C). How-
ever, pre-treatment with 2 μM of CP2 restored the uptake
of LacCer in HD cells to approximately 60% of that in
control neurons (Figure 4B, C). Thus, CP2 partially
restores lipid trafficking defect caused by expression of
mhtt, and the beneficial effect of CP2 is evident prior to
visible formation of aggregates.
Treatment with TP compounds prevents cholesterol 
accumulation in neurons caused by expression of mhtt
Since CP2 has been found to restore lipid trafficking in
primary striatal neurons expressing mhtt, we next investi-
gated whether CP2 and its analogues could also avert
another early cellular defect found in HD neurons, the
accumulation of cholesterol [18]. To test this, we plated
embryonic (E17) striatal neurons from control and HD72
mice and immediately treated them with 2 μM of different
TP compounds. Neurons were kept under continues TP
treatment for 13 days, then cells were fixed and intracellu-
lar levels of free cholesterol were estimated and compared
to untreated neurons using filipin staining. Filipin is an
antibiotic that specifically binds free cholesterol and
could be visualized under the UV light [26]. Consistent
with our previous data, untreated HD72 neurons accumu-
lated significant amounts of cholesterol after 13 days in
culture relative to control neurons (Figure 5A, B). In con-
trast, in HD72 neurons kept in the presence of 2 μM CP2
cholesterol levels did not increase and were similar to con-
trol neurons 13 days after plating (Figure 5A, Day 13).
Thus, CP2 treatment effectively prevented accumulation
of cholesterol caused by mhtt expression.
Next, we compared the efficiency of different TP com-
pounds in preventing cholesterol accumulation in embry-
onic striatal HD neurons (Figure 5B). In control neurons,
pre-treatment with CP2, TP3 or TP4 did not affect choles-
terol levels as measured using filipin 13 days after plating
(Figure 5B, control neurons). However, treatment with 2
μM of TP3 or TP4 was as efficient in lowering cholesterol
in HD neurons as treatment with CP2 (Figure 5B, HD
neurons). All TP compounds effectively prevented choles-BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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Figure 3 (see legend on next page)BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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terol accumulation in HD neurons reducing it to the levels
observed in control cells. Thus, TP compounds appeared
not only to efficiently prevent aggregation caused by
expression of mhtt, but also suppress early cellular dys-
functions in HD neurons that precede aggregate forma-
tion.
Discussion
The use of small molecules to inhibit specific protein-pro-
tein interactions and prevent aggregation has important
potential therapeutic application [27,28]. The fact that in
most neurodegenerative disorders faulty proteins form
fibrils with very similar structure suggests that it is feasible
to find the molecular approach that could be effectively
applied in many disease [29]. However, formation of
detectable aggregates usually occurs later in disease pro-
gression and may not represent the primary cause of cel-
lular dysfunction. Therefore, it is important to evaluate
whether specific treatment modalities could not only
inhibit aggregation, but also alleviate cellular dysfunc-
tions that occur early in disease progression.
Previously, we reported that tricyclic pyrone molecules,
CP2 in particular, directly bind Aβ 42 oligomers and pre-
vent formation of Aβ fibrils in cellular and mouse models
for AD [15,16]. Here, we demonstrate that TP compounds
also efficiently block aggregate formation in HD. Pre-
treatment with CP2, the most efficient aggregate inhibitor
in the AD cell model, blocked formation of aggregates
caused by expression of truncated form of mhtt in both
cultured primary striatal neurons and glial cells. Moreo-
ver, treatment with TP compounds alleviated early cellular
defects associated with HD that preclude aggregate forma-
tion. Specifically, TP treatment partially restored clathrin-
independent endocytosis and eliminated cholesterol
accumulation in mhtt-expressing neurons. It will be
important to test whether TP compounds demonstrate
similar efficacy in vivo in animal models representing HD.
Htt is ubiquitously expressed with highest levels in neu-
rons [30-32]. Both htt and mhtt interact with a large vari-
ety of cellular proteins involved in cytoskeletal dynamics
[33,34], clathrin-dependent and independent endocytosis
[18,35], axonal transport [36-38], postsynaptic signaling
[13] and transcription [39]. Expansion of the poly-
glutamine repeat in htt alters its interactions with cellular
proteins disrupting their functions and contributing to
pathology [40,41]. In our previous study, we demon-
strated that application of cav1 siRNA restored clathrin-
independent endocytosis and eliminated cholesterol
accumulation in HD neurons suggesting that interaction
between mhtt and cav-1 underlies these cellular defects
[18]. In the present experiments, treatment with TP com-
pounds did not affect cellular levels of mhtt or cav-1 in
neurons (data not shown). Thus, it is feasible that TP com-
pounds could bind mhtt and not only prevent its aggrega-
tion but also block mhtt interaction with its targets.
Preventing aberrant interactions could be beneficial, how-
ever additional experiments to demonstrate the specificity
and efficiency of this approach are necessary.
Originally, TP compounds were synthesized based on the
structures of pyripyropene A, an inhibitor of acyl-
CoA:cholesterol acyltransferase (ACAT) [42]. ACAT is an
endoplasmic reticulum-resident enzyme that regulates
intracellular cholesterol homeostasis by converting excess
free cholesterol to cholesteryl esters [43]. ACAT inhibitors
have been shown to effectively suppress generation of Aβ,
the major toxic component of senile plaques in AD, the
disease where cholesterol is known to be an important
risk factor [44-47]. One of the explanations of the reduced
free cholesterol levels in the cells is the demonstration
that ACAT inhibitors increase the expression of choles-
terol efflux transporter ATP-binding cassette transporter 1
(ABCA1) [48,49]. However, the molecular mechanism of
ACAT action remains to be elucidated. We found that all
three TP compounds used in this study, while only par-
tially restoring clathrin-independent endocytosis, effec-
tively reversed mhtt-induced cholesterol accumulation in
Treatment with CP2 prevents aggregate formation caused by expression of truncated form of mhtt in neurons and glial cells Figure 3 (see previous page)
Treatment with CP2 prevents aggregate formation caused by expression of truncated form of mhtt in neurons 
and glial cells. A. Transfection with truncated N-terminal form of mhtt with 82 polyglutamines (GFP-HD82) causes forma-
tion of aggregates (arrows) in striatal neurons (a) and glial cells (b) from control mice. Expression of htt fragment with 19 pol-
yglutamines (GFP-HD19) does not cause formation of aggregates (e, f). Pre-treatment with 2 μM of CP2 prevents formation of 
aggregates in cells transfected with GFP-HD82 (c, d). Images of live cells were taken using LSM 510 confocal microscope with 
100× oil DIC lens (1.4 na). Scale bar, 10 μm. B. Quantification of aggregate formation in neurons and glial cells from control 
mice with and without CP2 treatment. C. Treatments with TP compounds do not affect the expression of mhtt in primary 
neurons from HD mice. Neurons (E17) from HD mouse were treated with different doses of CP2, TP3, and TP4 for 6 days. 
Western Blot analyses were performed using specific monoclonal anti-huntingtin antibody 2166 (1:3000, Chemicon). Lane 1 – 
HD neurons, no treatment; lane 2 – HD neurons treated with 2 μM CP2; lane 3 – HD neurons treated with 5 μM CP2; lane 4 
– HD neurons treated with 2 μM TP3; lane 5 – HD neurons treated with 2 μM TP4. Anti-tubulin antibody (DM1A, 1:6000, 
Sigma) was used as loading control.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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Treatment with CP2 restores caveolin-related endocytosis inhibited by mhtt expression Figure 4
Treatment with CP2 restores caveolin-related endocytosis inhibited by mhtt expression. A. Treatment with CP2 
does not affect internalization of fluorescently labelled Tfn (red) in control or HD neurons. Images represent internalization of 
Tfn in live neurons 10 min after addition to the cells. Tfn internalization and localization were indistinguishable in untreated and 
CP2-pretreated control and HD cells. Data for 2 μM CP2 treatment is shown. Scale bar, 5 μm. B. Internalization of LacCer 
(green) is inhibited in striatal HD72 neurons (HD72, middle panel) comparing to control neurons. Treatment with 2 μM CP2 
restores internalization of LacCer in HD72 neurons (HD72+2 μM CP2). Images of live cells in A and B were acquired using 
LSM 510 confocal microscope with 100× oil DIC lens (1.4 na). Scale bar, 5 μm. C. Quantification of Tfn and LacCer internaliza-
tion in control and HD72 striatal neurons with and without CP2 treatment acquired in experiments shown in A and B. At 
least 10 cells were taken into analysis in each 3 independent experiments. *, p < 0.001.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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HD neurons. These observations suggest that TP com-
pounds possess a complex mechanism of action. First,
they may act as small molecules that directly bind faulty
proteins preventing aggregation and blocking protein-
protein interactions. Additionally, they may also affect
cholesterol homeostasis by regulating cellular cholesterol
efflux.
Conclusion
In summary, we have demonstrated that TP compounds
effectively inhibit mhtt-induced aggregation in HD neu-
rons and glial cells. Additionally, treatment with TP com-
pounds alleviated cholesterol accumulation and restored
clathrin-independent endocytosis, early neuronal defects
caused by expression of full-length mhtt that preclude
aggregate formation. Our data suggest TP compounds
may be used as lead molecules for prevention or treatment
of neurodegenerative diseases including HD and AD.
Methods
Animals and neuronal cell cultures
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee. The fol-
lowing mouse models were used: control FVB/N [50] with
7 glutamines in mouse endogenous htt homologue and
HD transgenic YAC (yeast artificial chromosome) model
expressing full-length human HD cDNA containing 72
polyglutamines (HD72) [19]. Preparation and culturing
Treatment with CP2 and other TP compounds prevents cholesterol accumulation in HD neurons Figure 5
Treatment with CP2 and other TP compounds prevents cholesterol accumulation in HD neurons. A. Intracellu-
lar cholesterol levels in striatal neurons from control (C) and HD72 (HD) mice with and without CP2 treatment at different 
days in culture. Control neurons do not accumulate cholesterol; HD neurons without CP2 treatment accumulate cholesterol 
to high extent than control neurons (13 DIC). Treatment with CP2 prevented cholesterol accumulation in HD neuron at 13 
DIC. At least 15 cells were taken into analysis for each data point. *, p < 0.001. B. Different TP compounds prevent cholesterol 
accumulation in HD neurons with similar efficiency. Data represent intracellular cholesterol levels in untreated control and HD 
neurons and neurons treated with 2 μM of different TP compounds on day 13 in culture. Numbers represent relative fluores-
cence units of filipin staining. At least 10 cells in each experiment were taken into analysis.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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of primary striatal neurons were performed as described
in Supplemental Material in [17]. Briefly, mice were anes-
thetized with ether on gestational day 17 and fetuses were
rapidly removed. Fetal brains were extracted and placed in
sterile HEPES- buffered saline (HBS) (pH 7.3). The ventral
part of the medial ganglionic eminence (the developmen-
tal precursor to the striatum) was dissected under a micro-
scope in sterile conditions. Tissue was placed in 2 mg/1 ml
papain (Warthington, NJ) in HBS for 20 min at 37°C.
After two washes in HBS, the dissociated tissue was tritu-
rated in Dulbecco's modified Eagle's medium containing
10% Ham's F12 with glutamine (Gibco/BRL, Grand
Island, NY), 10% heat inactivated fetal calf serum
(Hyclone Laboratories Logan, UT) and 1× pen/strep anti-
biotic mixture. Cells were counted, diluted to 3 × 105 cells/
ml, and 2 ml of this stock was placed in each well of a 6-
well dish containing glass coverslips coated with poly-L-
ornithine (1 mg/2 ml sterile borate buffer, pH 8.4). Plated
cells were maintained in an incubator with 5% CO2 at
37°C. After 72 h in culture medium containing serum was
replaced with a serum-free Neurobasal-based medium
(without glutamine, Gibco/BRL, Grand Island, NY) con-
taining 1 × pen/strep antibiotic mixture and 1 × B27 sup-
plement (Gibco/BRL, Grand Island, NY). Quantification
of neurons and glia using specific antibody staining
(GFAP for astrocytes and neuron specific βIII-tubulin)
demonstrates that neurons represent 95% of cells present
on the coverslip. Such uniform neuronal cultures could be
obtained by substituting serum (+) medium for Neuroba-
sal medium that was specifically designed to support neu-
ronal development and suppress glia proliferation (glial
growth was found to be less than 0.5%) [51]. In cases
where experiments required especially pure neuronal cul-
tures, cells were treated with cytosine β-D-arabinofurano-
side (Ara-C, Sigma, MO) to a final concentration of 2 μM
after 3 and 5 days in culture to suppress proliferation of
the glial cells. Such conditions allowed obtaining fully
developed pure striatal neurons exhibiting synaptic activ-
ity as judged by staining with synapsin antibody and EM
examination of synaptic contacts [18,36]. All experiments
were performed in neurons 6 to 7 days in culture unless
specifically stated.
Synthesis of CP2 and TP3 compounds
Compounds CP2 and TP3 were synthesized as described
earlier. Briefly, a selective hydroboration of compound 1
with borane followed by hydrogen peroxide, mesylation
with methanesulfonyl chloride, and displacement with
adenine provided CP2 or TP3 [22].
Synthesis of compound TP4
Synthesis of (5aS,7S)-3-(2-acetoxyethyl)-7-isopropenyl-
1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano [4,3-b][1]benz-
opyran (compound 2, Figure 1). To a cold (-10°C) solu-
tion of 0.39 g (3.88 mmol) of diisopropylamine in 10 ml
of THF under argon was added 2.4 ml (3.88 mmol; 1.6 M
solution in hexanes) of n-butyllithium via syringe, and the
solution was stirred for 1 hour providing a LDA solution.
In another flask, a solution of 1.00 g (3.88 mmol) of com-
pound 1 (Figure 1) [22] in 5 ml of THF under argon was
cooled to -78°C. The LDA solution was added to the
pyrone solution at -78°C via cannula, followed by 0.83 g
(4.65 mmol) of HMPA. After 3 h of stirring, the solution
was added to a cold (-78°C) mixture of 1.16 g (38 mmol)
of paraformaldehyde in 5 ml of THF via cannula, and
stirred for 2 h. The reaction solution was warmed to 25°C,
diluted with 40 ml of aqueous ammonium chloride, and
extracted three times with dichloromethane. The com-
bined organic layer was washed with 40 ml of brine, dried
(MgSO4), concentrated, and subjected to column chroma-
tography on silica gel using a gradient mixture of hexane
and ethyl acetate as eluant to give 0.15 g (15% recovery)




23 = +23.7° (c 3.5, CHCl3); 1H NMR δ (ppm) 6.06 (s,
1 H), 5.86 (s, 1 H), 5.11 (dd, J = 11, 4.4 Hz, 1 H, C5a-H),
4.75 (s, 1 H, = CH2), 4.73 (s, 1 H, = CH2), 3.90 (t, J = 6.2
Hz, 2 H, CH2O), 2.69 (t, J = 6.2 Hz, CH2), 2.48 (m, 1 H),
2.20 ~1.70 (a series of m, 5 H), 1.73 (s, 3 H, Me), 1.34
~1.25 (m, 1 H); 13C NMR δ (ppm) 163.3, 162.1, 148.0,
132.8, 109.9, 109.1, 101.1, 98.2, 79.6, 59.6, 43.6, 40.0,
37.3, 32.6, 32.1, 30.5, 20.9. HRMS calculated for
C17H21O4 (M+H) 289.1440, found 289.1411.
A solution of 0.20 g (0.70 mmol) of the above compound
and 0.14 g (1.40 mmol) of acetic anhydride in 3 ml of
pyridine was stirred at 25°C under argon for 7 h. The solu-
tion was diluted with ethyl acetate and washed with 1 N
HCl, aqueous NaHCO3, and brine, dried (MgSO4), con-
centrated, and subjected to column chromatography on
silica gel using a gradient mixture of hexane and ether as
eluants to give 0.14 mg (62% yield) of compound 2.
[α]D
23 = +16.9° (c 0.15, CHCl3); 1H NMR δ (ppm) 6.10 (s,
1 H), 5.79 (s, 1 H), 5.13 (dd, J = 11.2, 4.8 Hz, 1 H, C5a-
H), 4.75 (s, 1 H, = CH2), 4.73 (s, 1 H, = CH2), 4.33 (t, J =
6.4 Hz, 2 H, CH2O), 2.76 (t, J = 6.4 Hz, CH2), 2.48 (m, 1
H), 2.20 ~1.70 (a series of m, 5 H), 1.74 (s, 3 H, Me), 1.28
(qd, J = 12.8, 4 Hz, 1 H); 13C NMR δ (ppm) 170.9, 163.0,
160.9, 147.9, 132.9, 110.0, 109.6, 100.8, 98.5, 79.6, 60.8,
43.6, 40.0, 33.6, 32.5, 32.1, 30.5, 20.1, 20.9. HRMS calcu-
lated for C19H23O5 (M+H) 331.1545, found 331.1536.
(5aS,7S)-3-(2-Acetoxyethyl)-7-(2-hydroxy-1-methyle-
thyl)-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano [4,3-
b][1]benzopyran. To a cold (-78°C) solution of 0.14 mg
(0.43 mmol) of compound 2 in 3 ml of THF under argon,
was added 0.43 ml (0.43 mmol) of BH3THF (1.0 M in
THF), and the solution was stirred at -78°C for 30 min
and kept at -20°C for 2 days. To the solution (0°C), 1 mlBMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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of water, 0.5 ml of 0.1% NaOH aqueous solution, and 0.5
ml of 30% H2O2 were added, and the resulting solution
was stirred for 1 h. The solution was extracted with dichlo-
romethane three times, the combined extract was washed
with aqueous NH4Cl, water, and brine, dried (MgSO4),
concentrated, and column chromatographed on silica gel
using a gradient mixture of hexane and diethyl ether as
eluants to give 72 mg (56% yield; based on unreacted
compound 2) of the title compound as a mixture of two
diastereomers (stereochemistry differs at the newly cre-
ated side chain carbon; not separable by silica gel column
chromatography) along with 20 mg (14% recovery) of
compound 2. 1H NMR δ (ppm) 6.07 (s, 1 H), 5.78 (s, 1
H), 5.10 (m, 1 H, C5a-H), 4.32 (t, J = 6.2 Hz, 2 H, CH2O),
3.56 (m, 2 H, CH2OH) 2.76 (t, J = 6.2 Hz, CH2), 2.47 (m,
1 H), 2.17 ~1.10 (a series of m, 7 H), 0.91 (d, J = 7 Hz, 1
H); 13C NMR δ (ppm) 170.9, 163.0, 160.9, 133.4, 118.1,
109.3, 100.8, 98.5, 79.9, 66.0, 60.8, 40.2, 39.5, 37.6, 37.5,
37.3, 33.6, 31.2, 21.0. HRMS calculated for C19H25O6
(M+H) 349.1651, found 349.1649.
(5aS,7S)-3-(2-Acetoxyethyl)-7- [(2-methanesulfonyloxy)-
1-methylethyl]-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano
[4,3-b][1]benzopyran. A solution of 85 mg (0.24 mmol)
of the above alcohol, 74 mg (0.73 mmol) of triethylamine
and 42 mg (0.37 mmol) of methanesulfonyl chloride
(MsCl) in 3 ml of dichloromethane was stirred under
argon at 25°C for 3 h, diluted with aqueous sodium bicar-
bonate, and extracted twice with dichloromethane. The
combined extract was washed with brine, dried (anhy-
drous Na2SO4), concentrated, and column chromato-
graphed on silica gel using a gradient mixture of hexane
and diethyl ether as eluants to give 94 mg (90% yield) of
the title compound. 1H NMR δ (ppm) 6.05 (s, 1 H), 5.76
(s, 1 H), 5.07 (m, 1 H, C5a-H), 4.29 (t, J = 6.3 Hz, 2 H,
CH2O), 4.10 (m, 2 H, CH2OS), 3.00 (s, 3 H, CH3S), 2.73
(t, J = 6.3 Hz, CH2), 2.47 (d, J = 14 Hz, 1 H), 2.17 ~1.10
(a series of m, 7 H), 2.02 (s, 3 H, CH3CO), 0.96 (d, J = 7
Hz, 1 H); 13C NMR δ (ppm) 170.9, 162.9, 162.3, 161.1,
132.7, 109.7, 100.7, 98.4, 79.4, 72.3, 60.8, 39.1, 37.6,
37.5, 37.4, 33.6, 32.3, 30.9, 13.3. HRMS calculated for
C20H27O8S (M+H) 427.1426, found 427.1434.
(5aS,7S)-3-(2-Acetoxyethyl)-7- [(1R) and (1S)- 2-(N3-
adenyl)-1-methylethyl]-1H,7H-5a,6,8,9-tetrahydro-1-
oxopyrano [4,3-b][1]benzopyran (TP4). A solution of 94
mg (0.22 mmol) of (5aS,7S)-3-(2-acetoxyethyl)-7- [(2-
methanesulfonyloxy)-1-methylethyl]-1H,7H-5a,6,8,9-tet-
rahydro-1-oxopyrano [4,3-b][1]benzopyran and 32 mg
(0.24 mmol) of adenine in 1.5 ml of N, N-dimethylaceta-
mide (DMA) was stirred under argon at 150°C for 7 h,
and cooled to 25°C. DMA was removed under reduced
pressure (70°C/0.5 mm Hg), and the residue of the distil-
lation was triturated with 5 ml of dichloromethane. To the
residue, 50 mg (0.59 mmol) of NaHCO3 and 3 ml of eth-
anol were added, and the mixture was subjected to a silica
gel column chromatography using a gradient mixture of
dichloromethane and ethanol as eluant to give TP4. 1H
NMR δ (ppm) 8.07 (s, C8'H of adenine), 8.01 & 8.00 (2s,
1 H, C2'H of adenine; 2 diastereomers), 6.10 (s, 1 H,
C10H), 5.79 & 5.78 (2s, 1 H, C4H), 5.05 (m, 1 H, C5aH),
4.54 (2dd, J = 13.5, 6.5 Hz, 1 H, CHN; 2 diastereomers),
4.34 & 4.33 (2t, J = 6.2 Hz, 2 H, CH2O; 2 diastereomers),
4.07 (dd, J = 13.5, 8 Hz, 1 H, CHN), 2.78 & 2.76 (2t, J =
6.2 Hz, 2 H, CH2; 2 diastereomers), 2.07 & 2.06 (2s, 3 H,
Me; 2 diastereomers), 2.60 ~1.22 (a series of m, 8 H), 0.91
(d, J = 7.0 Hz, 3 H, Me). 13C NMR δ (ppm) 182.0, 181.6,
164.8, 163.3, 161.1, 155.8, 152.9, 148.0, 141.6, 131.1,
129.6, 129.1, 121.3, 100.7, 79.1, 78.9, 63.8, 59.2, 50.5,
33.6, 29.9, 21.1, 15.1. The product was further purified on
a HPLC using acetonitrile, water, and TFA (1%) as sol-
vents to give pure TP4TFA salt. HRMS calculated for
C24H28N5O5 (M+H) 466.2090, found 466.2081.
Plasmid Construction and Transfection
Experiments were performed as described in [17]. Control
and mhtt plasmids were derived from insertion of
sequence into pEGFP-C1 vector (Clontech). GFP-HD con-
structs were generated by inserting truncated (amino acids
1–221) HD cDNA that contains 19 (HD19) or 82 (HD82)
CAG repeats, respectively (generous gift from C. A. Ross).
All plasmids were confirmed by sequencing. Primary stri-
atal neurons from control mice were transfected using
Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA)
and Nupherin™-neuron (BIOMOL, Plymouth Metting,
PA) according to the manufacturer's instructions. Briefly,
embryonic neurons (E17) were plated on glass coverslips
and cultured for 6 days. Half of the cells were kept under
CP2 from the first day of plating. Expression plasmids (4
μg) were mixed with 20 μl of Nupherin-neuron in 380 μl
of serum-free phenol red-free DMEM. After 30 min of
incubation, DNA mixture was added to lipofectamine
solution in DMEM at a ratio of 4:1 (liposome to DNA),
incubated for another 45 min and added to the cells for 4
hrs. Cells were washed 3 times with DMEM and main-
tained in the incubator at 37°C and 5% CO2. CP2-con-
taining media was used in transfection experiments with
cells that had been kept under CP2 prior to transfection.
Cells were observed for formation of inclusions using
LSM 510 laser scanning microscope (C. Zeiss, Germany)
with 100× oil DIC lens (1.4 na). Imaging of the same cells
over time (2 days, every 6 hours) was performed using
microscopic incubator chamber with 5% CO2 and 37°C.
Software allowed recording the position of the cells to
ensure consecutive imaging of the same cell over time. At
least 10 cells were taken into analysis from at least three
independent experiments.BMC Neuroscience 2009, 10:73 http://www.biomedcentral.com/1471-2202/10/73
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Western blot analysis
Neurons from HD mice were plated and immediately
treated with different doses of CP2 (2 and 5 uM), TP3 (2
uM) and TP4 (2 uM). Cells were kept under these condi-
tions for 6 days. Treated and untreated HD cells were col-
lected, lysed and subjected to the Western Blot analysis on
4–15% gradient SDS-Tris gels with 30 μg of protein
loaded in each well. Htt and mhtt were detected using spe-
cific monoclonal anti-huntingtin antibody 2166 (1:3000,
Chemicon). Monoclonal Tubulin DM1A antibody
(1:6000, Sigma) was used for loading control. Horserad-
ish peroxidase-conjugated anti-mouse (1:24000) second-
ary antibody was used.
Filipin staining in neurons
Striatal neurons from control and HD72 mice were plated
on poly-L-ornithine covered glass coverslips in 6-well cul-
ture dishes in the serum-containing medium. Half of the
cells was treated with 2 μM CP2 at the moment of plating
and kept under that treatment till the day of analysis. Cells
were cultured for 3 days, then medium was switched to
Neurobasal (NB, cholesterol-free) medium, and cells were
cultured for additional 9 days in the presence of CP2.
Every third day after switch 1 ml of medium in the cell cul-
ture dish was replaced with 1 ml of fresh NB medium
(CP2 was kept at the 2 μM concentration all the time).
Cells were fixed with 4% paraformaldehyde (PFA) on day
3, 6, and 13 after plating. Coverslips were washed 3 times
with PBS, incubated 30 min with glycine (75 mg in 100
ml of PBS), and filipin solution (100 μg/ml, Polysciences,
Inc., Warrington, PA) was applied for 30 min at room
temperature. Cells were washed in PBS and immediately
observed under the microscope (LSM 510, C. Zeiss) using
100× magnification.
Untreated neurons and neurons treated with 2 μM CP2
were compared side by side for intensity of filipin stain-
ing. Five to ten cells were imaged for every point. Experi-
ments with other TP compounds using different
concentrations were performed the same way.
Internalization of fluorescent transferrin (Tfn) and 
lactosylceramide (LacCer)
C5-BODIPY- fatty acid labeled analog of lactosylceramide
(LacCer) and Alexa Fluor 594 -labeled transferring (Tfn)
were from Molecular Probes. Striatal neurons 6 days after
plating on poly-L-ornithine coated glass coverslips were
washed with HMEM (10 mM HEPES-buffered MEM) at
room temperature, and then incubated with BODIPY-Lac-
Cer for 10 min at 37°C in the incubator with 5% CO2 to
induce endocytosis. After incubation, the medium was
replaced with ice-cold HMEM without glucose, and the
culture dishes were transferred to a 10°C bath. Fluores-
cent lipid present at the cell surface was removed by incu-
bating the cells (six times, 10 min each) with 5% fatty acid
free BSA in HMEM without glucose at 10°C. For other
experiments, cells were incubated with 7.5 μg/ml Alexa
Fluor 594-labeled Tfn for 10 min at 37°C. Excess of fluo-
rescent marker at the cell surface was removed by acid
stripping (HMEM, pH 3). Cells were imaged using confo-
cal laser scanning microscope LSM 510 (Carl Zeiss) with
100× or 63× oil DIC objective (1.4 na) with optical sec-
tion set to ~0.5 μm.
Control and HD72 non-treated and 2- and 5-μm CP2
treated cells were examined. Neurons were kept under
CP2 from the first day of plating till the internalization
experiments. Cells were imaged side-by-side using the
same settings. Image analysis was done using LSM 510
Physiology software. Student t-test was applied to deter-
mine statistical significance between fluorescence read-
ings. Ten to fifteen neurons from three independent
platings were taken into analysis.
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